Molecular mechanisms of the medicines for COVID-19
国立国会図書館館内限定公開
収録元データベースで確認する
国立国会図書館デジタルコレクション
デジタルデータあり
公開元のウェブサイトで確認する
DOI[10.1246/bcsj.20220179]のデータに遷移します
全国の図書館の所蔵
国立国会図書館以外の全国の図書館の所蔵状況を表示します。
所蔵のある図書館から取寄せることが可能かなど、資料の利用方法は、ご自身が利用されるお近くの図書館へご相談ください
書誌情報
この資料の詳細や典拠（同じ主題の資料を指すキーワード、著者名）等を確認できます。
- 資料種別
- 記事
- 著者・編者
- Makoto Komiyama
- 出版年月日等
- 2022-07-14
- 出版年（W3CDTF）
- 2022-07-14
- タイトル（掲載誌）
- Bulletin of the Chemical Society of Japan
- 巻号年月日等（掲載誌）
- 95(9)
- 掲載巻
- 95(9)
- ISSN（掲載誌）
- 1348-0634
- ISSN-L（掲載誌）
- 0009-2673
- 本文の言語コード
- eng
- DOI
- 10.1246/bcsj.20220179
- 国立国会図書館永続的識別子
- info:ndljp/pid/12686451
- コレクション（共通）
- コレクション（障害者向け資料：レベル1）
- コレクション（個別）
- 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > 学術機関 > 学協会
- 収集根拠
- オンライン資料収集制度
- 受理日（W3CDTF）
- 2023-03-07T17:43:09+09:00
- 保存日（W3CDTF）
- 2023-01-20
- 記録形式（IMT）
- application/pdf
- オンライン閲覧公開範囲
- 国立国会図書館内限定公開
- デジタル化資料送信
- 図書館・個人送信対象外
- 遠隔複写可否（NDL）
- 可
- 掲載誌（国立国会図書館永続的識別子）
- info:ndljp/pid/12686450
- 連携機関・データベース
- 国立国会図書館 : 国立国会図書館デジタルコレクション
- 要約等
- コレクション : 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > 学術機関 > 学協会
- DOI
- 10.1246/bcsj.20220179
- 関連情報（URI）
- 参照
- Liquid–Liquid and Liquid–Solid Interfacial NanoarchitectonicsBio-gel nanoarchitectonics in tissue engineeringInterface-interactive nanoarchitectonics: solid and/or liquidMolecular nanoarchitectonics: unification of nanotechnology and molecular/materials scienceMaterials Nanoarchitectonics: Collaboration between Chem, Nano and MatEngineering dynamic and interactive biomaterials using material nanoarchitectonics for modulation of cellular behaviorsDisease Diagnosis with Chemosensing, Artificial Intelligence, and Prospective Contributions of NanoarchitectonicsPorous Boron Nitride Nanoarchitectonics for Environment: Adsorption in WaterChemistry of Materials Nanoarchitectonics for Two-Dimensional Films: Langmuir–Blodgett, Layer-by-Layer Assembly, and NewcomersInterfacial nanoarchitectonics with porphyrins and related molecules: Langmuir-Blodgett method and layer-by-layer assemblyCovalent nanoarchitectonics: Polymer synthesis with designer structures and sequencesNanoarchitectonics in combat against bacterial infection using molecular, interfacial, and material toolsNanoarchitectonics: the method for everything in materials science
- 参照
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)Structure and mechanism of the complex between cytochrome P4503A4 and ritonavirRemdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potencyEngineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19Extremely potent human monoclonal antibodies from COVID-19 convalescent patientsCrystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332Big data and simple models used to track the spread of COVID-19 in citiesCovalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main proteaseStructure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitorsTemplate-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of actionDiscovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike GlycoproteinCharacterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like ProteaseThe Potential Therapeutic Effect of RNA Interference and Natural Products on COVID-19: A Review of the Coronaviruses InfectionTherapeutic approaches and vaccination in fighting COVID-19 infections: A reviewDiscovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19mRNA Vaccines in the COVID-19 Pandemic and BeyondSARS-CoV-2 neutralizing antibody structures inform therapeutic strategiesDiscovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivirProbable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 OutbreakRemdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sitesThe SARS-CoV-2 main protease as drug targetStructural and functional conservation of the programmed −1 ribosomal frameshift signal of SARS coronavirus 2 (SARS-CoV-2)An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesisRole of the Eye in Transmitting Human Coronavirus: What We Know and What We Do Not KnowMolnupiravir: A new candidate for COVID‐19 treatmentMolnupiravir: coding for catastropheProteases and protease inhibitors in infectious diseasessiRNA Therapeutics against Respiratory Viral Infections—What Have We Learned for Potential COVID‐19 Therapies?Crystal structure of SARS-CoV-2 papain-like proteaseFluorine in Medicinal Chemistry: In Perspective to COVID-19Aptamers for Anti-Viral Therapeutics and DiagnosticsAptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteinsOral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant RecipientsCharacteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in ChinaResearch and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus DiseasesA Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung CellsBroad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2Nucleoside analogues for the treatment of coronavirus infectionsβ-<scp>d</scp>-<i>N</i>4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian CellsAntivirals for COVID-19: A critical review1′-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replicationZoonotic origins of human coronavirusesS-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systematic reviewSmart transformable nanomedicines for cancer therapySmall interfering RNA: a tailored approach to explore the therapeutic potential in COVID-19Nanoparticles‐assisted delivery of antiviral‐siRNA as inhalable treatment for human respiratory viruses: A candidate approach against SARS‐COV‐2Prospects for RNAi Therapy of COVID-19The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compoundsCOVID-19 Vaccines: Adenoviral VectorsExploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy SimulationsAptamer Blocking Strategy Inhibits SARS‐CoV‐2 Virus InfectionSmart cancer nanomedicineThe complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discoveryStructural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by CamostatMolnupiravir promotes SARS-CoV-2 mutagenesis via the RNA templateNovel human coronavirus (SARS-CoV-2): A lesson from animal coronavirusesStructural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNAJAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortalityRNAi Technology and Investigation on Possible Vaccines to Combat SARS-CoV-2 InfectionIdentification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agentsStrategies for engineering advanced nanomedicines for gas therapy of cancerDNA‐Based Nanoarchitectures as Eminent Vehicles for Smart Drug Delivery SystemsCamostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activitySmall-Molecule Antiviral β- <scp>d</scp> - <i>N</i> <sup>4</sup> -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to ResistanceRecent advances in natural polymer-based drug delivery systemsSARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorMechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodiesMERS-CoV papain-like protease has deISGylating and deubiquitinating activitiesConsiderations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infectionDrug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 TherapeuticsPotent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerabilitySARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effectsRemdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroPsychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemicReview article: gastrointestinal features in COVID‐19 and the possibility of faecal transmissionApproved Antiviral Drugs over the Past 50 YearsAn orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in miceAn Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule ChemotherapySARS‐CoV‐2 viral spike G614 mutation exhibits higher case fatality rateClinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical recordsStructural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2Papain-like protease regulates SARS-CoV-2 viral spread and innate immunityTheranostic DNAzymesMapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution SerologyCoronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading ExoribonucleaseDynamism of supramolecular DNA/RNA nanoarchitectonics: From interlocked structures to molecular machinesAccount/Review for Materials Innovation : Molecular Imprinting : Materials Nanoarchitectonics with Molecular InformationUltrasound-activated nanomaterials for therapeuticsMolecular-level anatomy of SARS-CoV-2 for the battle against the COVID-19 pandemic2-dimensional nanomaterials with imaging and diagnostic functions for nanomedicine : a review
- 連携機関・データベース
- 国立情報学研究所 : CiNii Research
- 提供元機関・データベース
- 雑誌記事索引データベースCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossref
- 書誌ID（NDLBibID）
- 12686451